



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Key concepts of orphan designation and latest developments

SME Workshop 26 April 2013

Presented by: Jordi Llinares
Head of orphan medicines

An agency of the European Union





Outline

Overview orphan designation

Orphan designation procedure and criteria

Incentives for orphan drugs

Practical considerations for SMEs

A “dream” example

Latest developments



Purpose of the Regulation

- To provide incentives for research, marketing and placing on the market designated orphan medicinal products
- To set up system for designation of orphan medicines





Main characteristics orphan designation

For medicinal products for human use

Procedure free of charge

Can be requested at any stage of development

Sponsor can be either company or individual

- Established in the EEA (EU, Ice, Liech, Nor)

European Commission Decision gives access to incentives



Incentives (I)

- Fee reduction / exemption (annually reviewed)
 - Extended incentives for Small and Medium Sized Enterprises (SMEs)
- Market exclusivity (10 years)
- Protocol assistance
- Community marketing authorisation
- National incentives (inventory from European Commission)



Incentives (II)

10-year market exclusivity

(+ 2 if paediatric indication – completion investigation plan)

- Protection against
 - similar products
 - Molecular structure
 - mech of action
 - for same indication
 - Three derogations (→ access to market even if similar)
 - Sponsor's consent
 - Lack of supply
 - Clinical superiority




Fee reductions

- Annually EU allocated special fund to cover fee reductions (approx. 6 million Euro)
- EMA has consistently kept maximum coverage for SMEs
- Academia and SME responsible for 79% development of advanced therapies
- Policy reviewed annually, needed revision in 2013 according to current budget



Allocation funds for fee reductions (2012)

Use EU fund






Protocol assistance

- Protocol assistance \cong scientific advice
 - Questions on quality-efficacy-safety
 - Questions on significant benefit
 - Company position required
 - SAWP provides answers

 - CHMP adopts answers
 - COMP involved if issues on benefit



Protocol assistance





Designation criteria

RARITY (prevalence) / RETURN OF INVESTMENT

- Medical condition affecting not more than 5 in 10,000 in the EU (around 250,000 people)
- Without incentives it is unlikely that the marketing of the product would generate sufficient return to justify the necessary investment

SERIOUSNESS


- Life –threatening or chronically debilitating

ALTERNATIVE METHODS AUTHORISED **EXCLUSIVE for EU**

- If satisfactory method exist the sponsor should establish that the product will be of significant benefit



The designation process in the EU





Committee for Orphan Medicines (COMP)

- 1 elected Chair (Prof Bruno Sepodes)
- 1 Representative per Member State
- 3 Patients' Representatives appointed by Eur. Commission
- 3 Members appointed by Eur. Commission on proposal from Agency
- 1 Member for Norway and 1 for Iceland

TOTAL: 33 members + 2 non voting




COMP responsibilities






Evolution orphan designations in the EU



- Approx 70% success rate
- Re-submission possible and common





Five tips for your application

Tell us that you are coming
(intent to file, email is enough)

Use our templates

- application model (sections A to E) ; application form (EU and EMA/FDA)

Use our web resources

- Prevalence
- Translations
- National formularies

Use available guidance

- Format and content guideline
- Application guidance

Ask for a pre-submission (email us!)



Browser address bar: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000519.jsp&mid=WC0b01ac05804ece5e

Search: citibank uk

Navigation: Home, Back, Forward, Stop, Refresh, Print, Mail, RSS, etc.

Bookmarks: Favorites, A disappointing consultati..., Web Slice Gallery, diccionariois, europa, manuals, organisations, other, AlertFind by MessageOne, Bartleby.com Great Books..., CEBM - Centre for Evidenc...

Open tabs: Market authorisati..., Webtop, Jordi, Webtop, RR_Proposal_05 - ..., Orphans, Agenda, European Medi... X



Text size: A A A

Site-wide search



Follow us:

European Medicines Agency logo with link to homepage

- Home
- Find medicine
- Regulatory**
- Special topics
- Document search
- News & events
- Partners & networks
- About us

Quick links

Human medicines

Pre-authorisation

Post-opinion

Post-authorisation

Product information

Scientific advice and protocol assistance

Scientific guidelines

Innovation Task Force

Regulatory and procedural guidance

SME office

Paediatric medicine

Orphan designation

Legal background

How to apply

Submission deadlines

Home ▶ Regulatory ▶ Human medicines ▶ Orphan designation ▶ How to apply

How to apply for orphan designation

Email Print Help Share

This page provides information for sponsors on how to apply for **orphan designation for a medicine**.

Notification of intention to submit

Sponsors should notify the European Medicines Agency of their **intention** to submit an application at least two months prior to the planned submission date by sending an e-mail to orphandrugs@ema.europa.eu. The notification should include:

- ▶ the active substance;
- ▶ the proposed orphan indication;
- ▶ the name and address of the sponsor;
- ▶ the planned submission date for the designation application.

Presubmission meetings

The Agency strongly encourages sponsors to request a **presubmission meeting** with the Agency prior to filing an application.

Presubmission meetings usually take place via teleconference, unless the sponsor has a strong preference to come to the Agency in person.

Where possible, sponsors should request a pre-submission meeting at least two months prior to filing. Presubmission meetings for orphan designation are free of charge.

Related information

- ▶ [Orphan designation](#)
- ▶ [Medicines for rare diseases: background information](#)

Contact point:

orphandrugs@ema.europa.eu





Browser address bar and tabs showing URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_detail_000014.jsp&mid=WC0b01ac058061ecb9



Text size: A A A Site-wide search GO Follow us: Twitter RSS

- Human medicines
Pre-authorisation
Post-opinion
Post-authorisation
Product information
Scientific advice and protocol assistance
Scientific guidelines
Innovation Task Force
Regulatory and procedural guidance
SME office
Paediatric medicine
Orphan designation
Legal background
How to apply
Submission deadlines

Home Regulatory Human medicines Orphan designation How to apply Questions and answers

Questions and answers: Orphan-designation application

Email Print Help Share

This page lists the questions that sponsors may have on applying for orphan designation.

If you have a question that is addressed here, forward your request to orphandrugs@ema.europa.eu.

Back to top

Expand all items in this list

- 1. What is the legal basis for orphan designation?
2. Can an application for orphan medicinal product designation be submitted at any time in the development process?
3. Can an application for marketing authorisation be submitted before the application for orphan medicinal product designation has obtained an opinion and/or designation? If so, can a fee reduction be granted on condition or refunded once the designation is obtained?
4. Can a product already authorised for a non-orphan indication in the European Union (EU) receive orphan designation for another indication which is orphan?
5. If a medicinal product has already been granted orphan drug designation in the United States or Japan, would this be automatically accepted for the EU?
6. Once orphan designation is granted, will it be possible to apply for a reduction in fees also for scientific advice, variations and annual fee, or only for a reduction in fees for the marketing authorisation application?
7. What are the sponsor's options in case of negative outcome for orphan designation? What information is published in



Status of Orphan Marketing Authorisation Applications: 78 granted to date

Adopted positive opinion

- 1 awaiting decision

Ongoing applications in review process

- 27 applications in review process

Variations / Line Extensions in review process

- 3 applications in review process

Negative outcomes for orphan MAA

- 56 applications withdrawn
- 10 negative decisions/refusals




Latest developments

- Strong EU and international support to research in rare diseases (Horizon 2020 and IRDiRC)
- Increasing international collaboration between regulators:
 - Administrative simplification / harmonisation
 - Continuous improvement (web linking, consultation on procedures)



Let's dream



Plan your strategy

Understand the step approach and use regulatory collaboration for your benefit



Of the 12 projects in the article nine for orphan designated products

Cordis website: three additional projects granted that involve development of orphan drugs:

- Drugsford (inherited photoreceptor degeneration)
- Eurofancolen (fanconi anaemia)
- Aipgene (intermittent acute porfuria)

Rare disease project	Funding (million)
→ Neuromics: integrated European omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases	€12
RD-CONNECT: an integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research	€12
EURenOmics: European Consortium for high-throughput research in rare kidney diseases	€12
BALANCE: development of a bioartificial liver therapy in acute liver failure	€6
→ DevelopAKUre: clinical development of nitisinone for alkaptonuria	€6
→ FIGHT-HLH: first targeted therapy to fight hemophagocytic lymphohistiocytosis	€6
→ GAPVAC: glioma actively personalized vaccine consortium	€6
→ MeuSIX: clinical trial of gene therapy for mucopolysaccharidosis type VI — a severe lysosomal storage disorder	€6
→ Net4CGD: gene therapy for X-linked chronic granulomatous disease	€6
→ PREVENTROP: new approach to treatment of the blinding disease retinopathy of prematurity	€6
→ PROFNAIT: development of a prophylactic treatment for the prevention of fetal/neonatal alloimmune thrombocytopenia	€6
→ Traumakine: interferon-beta treatment of acute respiratory distress syndrome	€6



Where to have more information

The screenshot shows the European Medicines Agency (EMA) website. The 'Special topics' menu item is circled in red. A red arrow points from this menu item to a list of topics under the letter 'M', which is also circled in red. The list includes 'Medicines and emerging science', 'Medicines for children', 'Medicines for older people', and 'Medicines for rare diseases'. The 'Medicines for rare diseases' item is highlighted with a red oval.

Home Find medicine Regulatory **Special topics** Document search News & events Partners & networks About us Quick links

Special topics

This section of the website gives information on **topics and issues of special interest** where the European Medicines Agency plays a role. New topics are added regularly.

A

- Advanced therapies
- Antimicrobial resistance

B

- Benefit-risk methodology
- Biological and chemical agents
- Biosimilar medicines

D

- Disease areas

F

- Falsified medicines

G

- Generic medicines

M

- Medicines and emerging science
- Medicines for children
- Medicines for older people
- Medicines for rare diseases

P

- Pandemic influenza

R

- Regulatory science

S

- Safety monitoring of medicines

T

- Transparency



European Medicines Agency - Human medicines - EU/3/05/267 - Windows Internet Explorer

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2009/11/human_orphan_000273.jsp&mid=WC0b01ac058001d12b

Google

Favorites: A disappointing consultati... Web Slice Gallery | diccionar... | europa | manuals | organisations | other | AlertFind by MessageOne | Bartleby.com Great Books... | CEBM - Centre for Evidenc...

Shortcuts to docum... | European Hemophil... | Webtop | European Medici... X

Page | Safety | Tools



An agency of the European Union



Text size: A A A Site-wide search GO

Follow us: [Twitter icon] [RSS icon]

- Home
- Find medicine**
- Regulatory
- Special topics
- Document search
- News & events
- Partners & networks
- About us
- Quick links

- Human medicines
 - European public assessment reports
 - Patient safety
 - Pending EC decisions
 - Withdrawn applications
 - Paediatrics
 - Rare disease designations**
 - Medicines under evaluation
 - Medicines for use outside the EU
 - Referrals
 - Veterinary medicines
 - Herbal medicines for human use

Home > Find medicine > Human medicines > Rare disease designations

EU/3/05/267

Email Print Help Share

- Orphan designation**
- Key facts
- Review of designation

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in July 2008 on request of the sponsor.

On 10 March 2005, orphan designation (EU/3/05/267) was granted by the European Commission to Pfizer Limited, United Kingdom, for (Z)-N-[2-(diethylamino)ethyl]-5-[[5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (S)-2-hydroxysuccinate for the treatment of malignant gastrointestinal stromal tumours.

Expand all items in this list

- What are malignant gastrointestinal stromal tumours?
- What is the estimated number of patients affected by the condition?
- What treatments are available?
- How is this medicine expected to work?
- What is the stage of development of this medicine?
- Opinions on orphan medicinal product designations are based on the following three criteria:

Name	Language	First published	Last updated
EU/3/05/267: Public summary of positive opinion for orphan designation of (Z)-N-[2-(Diethylamino)ethyl]-5-[[5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (S)-2-hydroxysuccinate			

Sponsor's contact details:

Pfizer Limited
Ramsgate Road
Sandwich
Kent CT13 9NJ
United Kingdom
Telephone: +44 13 04 64 85 30
Telefax: +44 13 04 65 50 47

Patients' associations contact points:

The Association of European Cancer Leagues (ECL)
c/o Belgian Federation against Cancer
Chaussée de Louvain, 479
B-1030 Brussels
Belgium
Telephone: +32 2 743 3705
Telefax: +32 2 734 9250
E-mail: chartmann@cancer.be

Ligue Nationale Contre le Cancer
13 Av. de la Grande Armee
75116 Paris
France
Telephone: +33 1 45 00 00 17
Tefefax: +33 1 45 00 63 06
E-mail: ligue@ligue-cancer.net



Many thanks

any questions?

Jordi.Ilinares@ema.europa.eu

EMA website: <http://www.ema.europa.eu>



European Medicines Agency 2013. Reproduction and/or distribution of this document is possible for non-commercial purposes provided that EMEA is always acknowledged as the source in each copy. Citations may be made, provided the source is always acknowledged.

See:

<http://www.emea.europa.eu/htms/technical/dmp/copyritel.htm>